INFU · XBRL financial data

InfuSystem Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (INFU's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	97,388	102,382	109,914	125,785	134,861	143,436
Cost of goods and services sold	38,629	42,185	47,343	62,676	64,458	63,140
Gross profit	58,759	60,197	62,571	63,109	70,403	80,296
General and administrative	35,195	42,261	46,077	45,377	51,209	56,969
Total operating expenses	49,932	57,377	60,917	59,021	63,512	68,376
Operating income (loss)	8,827	2,820	1,654	4,088	6,891	11,920
Interest expense	1,255	1,377	1,402	2,170	1,777	1,299
Other income (expense)	(29)	(186)	(122)	(67)	(55)	2
Income tax expense (benefit)	(9,789)	(163)	112	979	2,714	3,996
Net income (loss)	17,332	1,420	18	872	2,345	6,627
Earnings per share, basic USD per share	0.86	0.07	0.00	0.04	0.11	0.32
Earnings per share, diluted USD per share	0.80	0.06	0.00	0.04	0.11	0.31
Weighted average shares, basic thousands of shares	20,107	20,520	20,649	21,024	21,272	20,658
Weighted average shares, diluted thousands of shares	21,717	22,050	21,547	21,646	21,707	21,097

Fiscal years (INFU's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	9,648	186	165	231	527	3,186
Accounts receivable	14,720	15,405	16,871	19,830	21,155	22,901
Inventory	3,001	3,939	4,821	6,402	6,528	5,391
Total current assets	29,771	22,065	24,779	30,620	32,165	36,336
Property and equipment, net	4,296	4,523	4,385	4,321	4,030	3,359
Right-of-use asset	4,461	4,241	4,168	6,703	5,374	4,178
Goodwill	0	3,710	3,710	3,710	3,710	3,710
Total assets	96,991	97,586	99,388	102,915	103,614	100,560
Accounts payable	6,779	7,862	8,341	8,009	9,848	10,821
Current portion of long-term debt	9,423	349	0	0	0	0
Total current liabilities	22,997	12,896	14,467	15,713	17,661	20,182
Long-term debt	29,378	32,748	33,157	29,101	23,864	19,625
Lease liability, non-current	3,864	3,670	3,761	5,799	4,560	3,427
Total liabilities	56,239	49,314	51,385	50,613	46,085	43,234
Accumulated deficit	(44,035)	(53,903)	(59,344)	(58,625)	(57,460)	(60,702)
Total stockholders' equity	40,752	48,272	48,003	52,302	57,529	57,326
Total liabilities and equity	96,991	97,586	99,388	102,915	103,614	100,560
Common shares outstanding (cover page) thousands of shares	20,337	20,548	20,893	21,265	21,009	20,215

Fiscal years (INFU's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	17,332	1,420	18	872	2,345	6,627
Stock-based compensation	2,610	6,404	3,825	4,074	4,460	4,363
Net cash from operating activities	20,280	18,316	17,517	11,223	20,459	24,408
Purchases of property and equipment	1,094	980	982	1,024	1,092	560
Net cash from investing activities	(12,162)	(21,315)	(11,478)	(6,734)	(13,239)	(6,790)
Share repurchases	0	560	5,459	153	1,180	9,869
Proceeds from long-term debt	37,587	76,191	—	—	—	—
Repayments of long-term debt	37,180	81,660	—	—	—	—
Net cash from financing activities	(1,117)	(6,463)	(6,060)	(4,423)	(6,924)	(14,959)
Net change in cash	7,001	(9,462)	(21)	66	296	2,659

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
InfuSystem Holdings	964	36,933	6,777*	19.9M	—	Q2 FY26 10-QJun 30, 2026
KORU Medical Systems	8,288	12,045	216*	46.2M	—	Q2 FY26 10-QJun 30, 2026
Neuronetics	22,106	41,962	1,238*	77.7M	—	Q3 FY26 10-QSep 30, 2026
Picard Medical	38	2,954	(1,352)*	2.3M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
LENSAR	13,565	16,495	(127)*	12.3M	106.8 quarters	Q2 FY26 10-QJun 30, 2026
Lakeland Industries	17,901	50,139	(404)*	9.9M	—	Q2 FY27 10-QJul 31, 2026
CVRx	64,586	15,705	(8,826)*	26.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TriSalus Life Sciences	46,288	11,407	(10,129)*	61.6M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.